Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.58 |
| ▸ | MME | P08473 | 11/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 9/20 | 0.55 |
| ▸ | ACE | P12821 | 8/20 | 0.52 |
| ▸ | CPA1 | P15085 | 7/20 | 0.52 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.51 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348297 | 1.00 | HPGDS (0.58) | HPGDSMMEACE2ACECPA1 | |
| SCHEMBL9109075 | 0.91 | HPGDS (0.56) | HPGDSMME | |
| SCHEMBL299180 | 0.85 | CTSC (0.49) | HPGDSMMEACE2ACECPA1 | |
| SCHEMBL28097066 | 0.85 | HPGDS (0.47) | HPGDSACE | |
| SCHEMBL24899372 | 0.84 | HPGDS (0.56) | HPGDSMMEACE2ACECPA1 | |
| SCHEMBL2074867 | 0.84 | CA1 (0.51) | HPGDS | |
| SCHEMBL16823433 | 0.84 | HPGDS (0.53) | HPGDSMMEACE2ACECPA1 | |
| SCHEMBL30995919 | 0.84 | MME (0.55) | HPGDSMMEACE2ACECPA1 | |
| SCHEMBL18262572 | 0.83 | CA2 (0.49) | HPGDSMME | |
| SCHEMBL20397627 | 0.83 | FPR2 (0.48) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391766-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | GENENTECH, INC. (US) | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391766-A1 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | VHL, HIF1AN, EGLN2 | HPGDS 98/4885MME 4519/4885ACE2 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.